8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jun 13, 2011)

Filed June 13, 2011For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on June 13, 2011, the promotion of Dr. Akshay K. Vaishnaw to Senior Vice President and Chief Medical Officer. This appointment signifies a key leadership enhancement within the company's medical and research operations. Dr. Vaishnaw, who has been a key member of Alnylam since 2006, most recently led the company's clinical research efforts. His expanded role as Chief Medical Officer suggests a greater strategic involvement in the company's drug development pipeline and clinical strategy, which is critical for a biotechnology firm focused on innovative therapeutics. Investors should view this as a positive step in strengthening the management team overseeing the progression of Alnylam's drug candidates.

Key Highlights

  • 1Akshay K. Vaishnaw, M.D., Ph.D. promoted to Senior Vice President and Chief Medical Officer.
  • 2Dr. Vaishnaw has been with Alnylam since January 2006 and previously served as Senior Vice President of Clinical Research.
  • 3Annual base salary for Dr. Vaishnaw increased to $385,000 from $359,805.
  • 4Stock option award granted for 100,000 shares of common stock.
  • 5Option exercise price set at $9.30 per share, reflecting the closing price on June 9, 2011.
  • 6Stock options vest over four years, with 25% vesting on the first anniversary and incremental quarterly vesting thereafter.

Frequently Asked Questions

Dr. Vaishnaw's promotion to Chief Medical Officer indicates an elevation of his role in overseeing Alnylam's medical strategy and clinical development. This is a critical leadership position for a pharmaceutical company, suggesting increased responsibility for guiding the company's therapeutic pipeline and regulatory interactions.

Dr. Vaishnaw was granted an option to purchase 100,000 shares of Alnylam's common stock at an exercise price of $9.30 per share. This award is designed to incentivize long-term performance and align his interests with shareholders. The options will vest over a four-year period, starting with 25% on the first anniversary of the grant date.

Yes, Dr. Vaishnaw's annual base salary has been increased to $385,000 from $359,805 as part of his promotion. In addition to the salary increase, he received a substantial stock option award, reflecting the company's investment in his continued leadership and contribution.